Elranatamab Side Effects

Medically reviewed by Drugs.com. Last updated on Mar 20, 2024.

Applies to elranatamab: subcutaneous solution.

Serious side effects of Elranatamab

Along with its needed effects, elranatamab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking elranatamab:

More common

• Agitation
• back pain
• being forgetful
• bladder pain
• bleeding gums
• bloody or cloudy urine
• blurred or double vision
• body aches or pain
• burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
• chest pain, discomfort, or tightness
• coma
• confusion
• confusion as to time, place, or person
• cough
• coughing up blood
• diarrhea
• difficult, burning, or painful urination
• dizziness
• drowsiness
• ear congestion
• fainting
• fast heartbeat
• fever or chills
• frequent urge to urinate
• hallucinations
• headache
• holding false beliefs that cannot be changed by fact
• increased menstrual flow or vaginal bleeding
• irritability
• lightheadedness
• loss of taste or smell
• loss of voice
• lower back or side pain
• mental depression or anxiety
• mood or mental changes
• muscle or bone pain
• nightmares or unusually vivid dreams
• nosebleeds
• paralysis
• pounding or rapid pulse
• prolonged bleeding from cuts
• rapid or irregular heartbeat
• red or black, tarry stools
• red or dark brown urine
• seizures
• shakiness and unsteady walk
• sleepiness or unusual drowsiness
• sneezing
• sore throat
• stiff neck
• stuffy or runny nose
• swelling
• trembling and shaking of the hands
• trouble breathing
• unsteadiness, trembling, or other problems with muscle control or coordination
• unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness
• unusual excitement, nervousness, or restlessness
• vomiting

Less common

• Decreased urine output
• hostility
• muscle twitching
• nausea
• pale skin
• rapid weight gain
• stupor
• swelling of the face, ankles, or hands
• ulcers, sores, or white spots in the mouth
• unusual bleeding or bruising

Rare

• Cool, sweaty skin
• inability to move the arms and legs
• sudden numbness and weakness in the arms and legs

Incidence not known

• Dark urine
• dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
• fast, pounding, or irregular heartbeat or pulse
• loss of appetite
• stomach pain, severe
• yellow eyes or skin

Other side effects of Elranatamab

Some side effects of elranatamab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

• Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
• constipation
• dry skin
• fall
• trouble sleeping

For Healthcare Professionals

Applies to elranatamab: subcutaneous solution.

General

The most common adverse reactions were cytokine release syndrome (CRS), fatigue, musculoskeletal pain, rash, injection site reaction, diarrhea, upper respiratory tract infection, decreased appetite, cough, nausea, and pyrexia. Serious adverse reactions occurred in 68% of patients and fatal reactions in 10%, including pneumonia and sepsis.^[Ref]

Cardiovascular

Very common (10% or more): Cardiac arrhythmia (16%)

Uncommon (0.1% to 1%): Cardiac failure, cardio-respiratory arrest, cardiogenic shock^[Ref]

Dermatologic

Very common (10% or more): Rash (25%), dry skin (13%), skin exfoliation (10%)^[Ref]

Rash includes erythema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculopapular, rash pustular, symmetrical drug-related intertriginous and flexural exanthema.^[Ref]

Gastrointestinal

Very common (10% or more): Diarrhea (36%), nausea (22%), constipation (15%), vomiting (14%)

Frequency not reported: Abdominal pain^[Ref]

Immunologic

Very common (10% or more): Cytokine release syndrome (58%), hypogammaglobulinemia (13%)^[Ref]

Local

Very common (10% or more): Fatigue (43%), injection site reaction (37%), pyrexia (21%), edema (18%)^[Ref]

Metabolic

Very common (10% or more): Decreased appetite (26%)

Uncommon (0.1% to 1%): Failure to thrive^[Ref]

Musculoskeletal

Very common (10% or more): Musculoskeletal pain (34%)^[Ref]

Nervous system

Very common (10% or more): Headache (18%), encephalopathy (15%), sensory neuropathy (13%), motor dysfunction (13%)

Common (1% to 10%): Immune effector cell-associated neurotoxicity syndrome (ICANS), Guillain-Barre syndrome^[Ref]

Encephalopathy includes agitation, altered state of consciousness, cognitive disorder, confusional state, delirium, depressed level of consciousness, disorientation, hallucination, lethargy, memory impairment, mental status changes, metabolic encephalopathy, somnolence, and toxic encephalopathy.

Sensory neuropathy includes burning sensation, dysesthesia, hypoesthesia, neuropathy peripheral, paresthesia, parosmia, peripheral sensorimotor neuropathy, peripheral sensory neuropathy, polyneuropathy, and sensory loss.

Motor dysfunction includes ataxia, balance disorder, gait disturbance, motor dysfunction, muscle contracture, muscle spasms, muscular weakness, peripheral motor neuropathy, peroneal nerve palsy, and tremor.^[Ref]

Other

Very common (10% or more): upper respiratory tract infection (34%), pneumonia (32%), sepsis (15%), urinary tract infection (12%), hemorrhage (13%), fall (10%), increased aspartate aminotransferase (40%), increased alanine aminotransferase (36%), decreased potassium (36%), decreased albumin (55%), increased alkaline phosphatase (34%), decreased creatinine clearance (32%), increased creatinine (28%), decreased lymphocyte count (91%), decreased hemoglobin (68%), decreased neutrophils (62%), decreased platelets (61%), decreased white blood cell (69%)

Common (1% to 10%): Febrile neutropenia, thrombosis

Frequency not reported: Thrombosis, COVID-19^[Ref]

Pneumonia includes COVID-19 pneumonia, lower respiratory tract infection, lower respiratory tract infection viral, pneumocystis jirovecii pneumonia, pneumonia, pneumonia adenoviral, pneumonia bacterial, pneumonia cytomegaloviral, pneumonia fungal, pneumonia influenzal, pneumonia pseudomonal, pneumonia viral.

Sepsis includes bacteremia, device-related bacteremia, device-related sepsis, escherichia bacteremia, escherichia sepsis, klebsiella sepsis, pseudomonal sepsis, sepsis, septic shock, staphylococcal bacteremia, staphylococcal sepsis, streptococcal sepsis, urosepsis.^[Ref]

Psychiatric

Very common (10% or more): Insomnia (13%)^[Ref]

Renal

Frequency not reported: Acute kidney injury^[Ref]

Respiratory

Very common (10% or more): Cough (24%), dyspnea (15%)

Uncommon (0.1% to 1%): Acute respiratory distress syndrome, pulmonary embolism

Frequency not reported: Congestion^[Ref]

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer